Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 4, 2012

View Archived Issues

New B-raf inhibitors presented by Array BioPharma and Genentech

Ablynx and Merck & Co. enter collaboration for Nanobody candidates

Intravenous dosing of GSK-322 investigated in healthy subjects

FDA approves extended-release liquid methylphenidate for ADHD

Phase III Abraxane trial meets primary endpoint

Astex begins phase II trial of SGI-110 in platinum-resistant recurrent ovarian cancer

PolyMedix presents new antimicrobials against biowarfare pathogens

Ipragliflozin has beneficial effects in Japanese patients with type 2 diabetes

Eravacycline compared to ertapenem in patients with intra-abdominal infections

Spanish researchers disclose new immunogenic compositions

Sanofi patents new 11-beta-HSD1 inhibitors

Merck Serono creates spin-off company to focus on neurodegenerative diseases

Ipsen provides update on hemophilia product agreement with Inspiration Biopharmaceuticals

Thrombolytic Science International begins phase I study of TS-01

Mallinckrodt completes acquisition

Athersys updates on MultiStem adult stem cell phase II study

Curis begins phase I trial of oral formulation of CUDC-101 in solid tumors

First data on once-weekly DPP IV inhibitor MK-3102 reported

Development and commercialization agreement reached for velusetrag for gastroparesis

Servier and EOS conclude collaboration and license agreement for E-3810

CBL-0102 receives U.S. orphan drug designation for hepatocellular carcinoma

Sanofi and Bristol-Myers Squibb restructure alliance

Omeros completes enrollment in second phase III OMS-302 trial

Phase Ib trial of RG-3039 commences

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...